In vitro Transport Ability of ABCC2 (G1249A) Polymorphic Variant Towards Anticancer Drugs

References

• Tiainen L, Tanner M, Lahdenperä O, et al. Bevacizumab combined with docetaxel or paclitaxel as first-line treatment of HER2-negative metastatic breast cancer. Anticancer Res. 2016;36(12):6431–6438. doi:10.21873/anticanres.1124127919965
   PubMed Web of Science ®Google Scholar
• Carbognin L, Sperduti I, Nortilli R, et al. Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: sensitivity analysis of randomized trials. Cancer Treat Rev. 2015;41(3):262–270. doi:10.1016/j.ctrv.2015.02.00325683304
   PubMed Web of Science ®Google Scholar
• Bronte G, Andreis D, Bravaccini S, et al. Sorafenib for the treatment of breast cancer. Expert Opin Pharmacother. 2017;18(6):621–630. doi:10.1080/14656566.2017.130902428335647
   PubMed Web of Science ®Google Scholar
• Shafei A, El-Bakly W, Sobhy A, et al. A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer. Biomed Pharmacother. 2017;95:1209–1218. doi:10.1016/j.biopha.2017.09.05928931213
   PubMed Web of Science ®Google Scholar
• Hida K, Kikuchi H, Maishi N, Hida Y. ATP-binding cassette transporters in tumor endothelial cells and resistance to metronomic chemotherapy. Cancer Lett. 2017;400:305–310. doi:10.1016/j.canlet.2017.02.00628216371
   PubMed Web of Science ®Google Scholar
• Wang Z, Sun X, Feng Y, et al. Dihydromyricetin reverses MRP2-mediated MDR and enhances anticancer activity induced by oxaliplatin in colorectal cancer cells. Anticancer Drugs. 2017;28(3):281–288. doi:10.1097/CAD.000000000000045927997436
   PubMed Web of Science ®Google Scholar
• Vos K, Sciuto CL, Piedade R, et al. MRP2/ABCC2 C1515Y polymorphism modulates exposure to lumefantrine during artemether-lumefantrine antimalarial therapy. Pharmacogenomics. 2017;18(10):981–985. doi:10.2217/pgs-2017-003228639487
   PubMed Web of Science ®Google Scholar
• Andersen V, Svenningsen K, Knudsen LA, et al. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology. World J Gastroenterol. 2015;21(41):11862–11876. doi:10.3748/wjg.v21.i41.1186226557010
   PubMed Web of Science ®Google Scholar
• Oliveira C, Joshee L, Bridges CC. MRP2 and the transport kinetics of cysteine conjugates of inorganic mercury. Biol Trace Elem Res. 2018;184(1):279–286. doi:10.1007/s12011-017-1163-328980184
   PubMed Web of Science ®Google Scholar
• Platt A, Xia Z, Liu Y, Chen G, Lazarus P. Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases. Pharmacogenet Genom. 2016;26(8):370–380. doi:10.1097/FPC.0000000000000226
   PubMed Web of Science ®Google Scholar
• Abla N, Chinn LW, Nakamura T, et al. The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene. J Pharmacol Exp Ther. 2008;325(3):859–868. doi:10.1124/jpet.108.13652318364470
   PubMed Web of Science ®Google Scholar
• Haenisch S, May K, Wegner D, Caliebe A, Cascorbi I, Siegmund W. Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet Genom. 2008;18(4):357–365. doi:10.1097/FPC.0b013e3282f974b7
   PubMed Web of Science ®Google Scholar
• Wen X, Joy MS, Aleksunes LM. In vitro transport activity and trafficking of MRP2/ABCC2 polymorphic variants. Pharm Res. 2017;34(8):1637–1647. doi:10.1007/s11095-017-2160-028405913
   PubMed Web of Science ®Google Scholar
• Han B, Gao G, Wu W, et al. Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients. Lung Cancer. 2011;72(2):238–243. doi:10.1016/j.lungcan.2010.09.00120943283
   PubMed Web of Science ®Google Scholar
• Wei D, Zhang H, Peng R, Huang C, Bai R. ABCC2 (1249G > A) polymorphism implicates altered transport activity for sorafenib. Xenobiotica. 2016;47:1–7.26999266
   PubMed Web of Science ®Google Scholar
• Megaraj V, Zhao T, Paumi CM, Gerk PM, Kim RB, Vore M. Functional analysis of nonsynonymous single nucleotide polymorphisms of multidrug resistance-associated protein 2 (ABCC2). Pharmacogenet Genomics. 2011;21(8):506–515. doi:10.1097/FPC.0b013e328348c78621691255
   PubMed Web of Science ®Google Scholar
• Hirouchi M, Suzuki H, Itoda M, et al. Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. Pharm Res. 2004;21(5):742–748. doi:10.1023/B:PHAM.0000026422.06207.3315180328
   PubMed Web of Science ®Google Scholar
• Dessilly G, Elens L, Panin N, Benjamin RS. ABCB1 1199G>A polymorphism (rs2229109) affects the transport of imatinib, nilotinib and dasatinib. Pharmacogenomics. 2016;17(8):883–890. doi:10.2217/pgs-2016-001227268766
   PubMed Web of Science ®Google Scholar
• Němcová-Fürstová V, Kopperová D, Balušíková K, et al. Characterization of acquired paclitaxel resistance of breast cancer cells and involvement of ABC transporters. Toxicol Appl Pharmacol. 2016;310:215–228. doi:10.1016/j.taap.2016.09.02027664577
   PubMed Web of Science ®Google Scholar
• Ehrlichova M, Vaclavikova R, Ojima I, et al. Transport and cytotoxicity of paclitaxel, docetaxel, and novel taxanes in human breast cancer cells. Naunyn Schmiedebergs Arch Pharmacol. 2005;372(1):95–105. doi:10.1007/s00210-005-1080-416059735
   PubMed Web of Science ®Google Scholar
• Chaisit T, Siripong P, Jianmongkol S. Rhinacanthin-C enhances doxorubicin cytotoxicity via inhibiting the functions of P-glycoprotein and MRP2 in breast cancer cells. Eur J Pharmacol. 2017;795:50–57. doi:10.1016/j.ejphar.2016.12.00227916559
   PubMed Web of Science ®Google Scholar
• Tecza K, Pamula-Pilat J, Lanuszewska J, Grzybowska E. Genetic polymorphisms and response to 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients. Oncotarget. 2016;7(41):66790–66808. doi:10.18632/oncotarget.1105327527855
   PubMedGoogle Scholar
• Chen P, Yan Q, Xu H, Lu A, Zhao P. The effects of ABCC2 G1249A polymorphism on the risk of resistance to antiepileptic drugs: a meta-analysis of the literature. Genet Test Mol Biomarkers. 2014;18(2):106–111. doi:10.1089/gtmb.2013.036224325761
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77(4):491–502. doi:10.1016/0092-8674(94)90212-77910522
   PubMed Web of Science ®Google Scholar
• Jabir RS, Naidu R, Annuar MA, Ho GF, Munisamy M, Stanslas J. Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity. Pharmacogenomics. 2012;13(16):1979–1988. doi:10.2217/pgs.12.16523215890
   PubMed Web of Science ®Google Scholar
• Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci. 2008;99(5):967–972. doi:10.1111/j.1349-7006.2008.00765.x18294295
   PubMed Web of Science ®Google Scholar
• Sun N, Sun X, Chen B, et al. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2010;65(3):437–446. doi:10.1007/s00280-009-1046-119568750
   PubMed Web of Science ®Google Scholar
• Subramanian N, Condic-Jurkic K, O’Mara ML. Structural and dynamic perspectives on the promiscuous transport activity of P-glycoprotein. Neurochem Int. 2016;98:146–152. doi:10.1016/j.neuint.2016.05.00527180050
   PubMed Web of Science ®Google Scholar
• van Hasselt JG, van Calsteren K, Heyns L, et al. Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. Ann Oncol. 2014;25(10):2059–2065. doi:10.1093/annonc/mdu14024713311
   PubMed Web of Science ®Google Scholar
• Ellis LC, Hawksworth GM, Weaver RJ. ATP-dependent transport of statins by human and rat MRP2/Mrp2. Toxicol Appl Pharmacol. 2013;269(2):187–194. doi:10.1016/j.taap.2013.03.01923562342
   PubMed Web of Science ®Google Scholar